164 related articles for article (PubMed ID: 26724538)
1. Development, characterization and antimalarial efficacy of dihydroartemisinin loaded solid lipid nanoparticles.
Omwoyo WN; Melariri P; Gathirwa JW; Oloo F; Mahanga GM; Kalombo L; Ogutu B; Swai H
Nanomedicine; 2016 Apr; 12(3):801-809. PubMed ID: 26724538
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles.
Omwoyo WN; Ogutu B; Oloo F; Swai H; Kalombo L; Melariri P; Mahanga GM; Gathirwa JW
Int J Nanomedicine; 2014; 9():3865-74. PubMed ID: 25143734
[TBL] [Abstract][Full Text] [Related]
3. Artemisinin and artemisinin plus curcumin liposomal formulations: enhanced antimalarial efficacy against Plasmodium berghei-infected mice.
Isacchi B; Bergonzi MC; Grazioso M; Righeschi C; Pietretti A; Severini C; Bilia AR
Eur J Pharm Biopharm; 2012 Apr; 80(3):528-34. PubMed ID: 22142592
[TBL] [Abstract][Full Text] [Related]
4. Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity.
Parashar D; Aditya NP; Murthy RS
Drug Deliv; 2016; 23(1):123-9. PubMed ID: 24786480
[TBL] [Abstract][Full Text] [Related]
5. Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance.
Nnamani PO; Ugwu AA; Ibezim EC; Kenechukwu FC; Akpa PA; Ogbonna JN; Obitte NC; Odo AN; Windbergs M; Lehr CM; Attama AA
Int J Nanomedicine; 2016; 11():6365-6378. PubMed ID: 27932882
[TBL] [Abstract][Full Text] [Related]
6. Development Insights of Surface Modified Lipid Nanoemulsions of Dihydroartemisinin for Malaria Chemotherapy: Characterization, and in vivo Antimalarial Evaluation.
Umeyor CE; Obachie O; Chukwuka R; Attama A
Recent Pat Biotechnol; 2019; 13(2):149-165. PubMed ID: 30514197
[TBL] [Abstract][Full Text] [Related]
7. An oral malaria therapy: curcumin-loaded lipid-based drug delivery systems combined with β-arteether.
Memvanga PB; Coco R; Préat V
J Control Release; 2013 Dec; 172(3):904-13. PubMed ID: 24021359
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo anti-malarial activity of novel harmine-analog heat shock protein 90 inhibitors: a possible partner for artemisinin.
Bayih AG; Folefoc A; Mohon AN; Eagon S; Anderson M; Pillai DR
Malar J; 2016 Dec; 15(1):579. PubMed ID: 27903279
[TBL] [Abstract][Full Text] [Related]
9. In vivo Antiplasmodial Activity of Curcumin-Loaded Nanostructured Lipid Carriers.
Rashidzadeh H; Salimi M; Sadighian S; Rostamizadeh K; Ramazani A
Curr Drug Deliv; 2019; 16(10):923-930. PubMed ID: 31663477
[TBL] [Abstract][Full Text] [Related]
10. Ameliorating the in vivo antimalarial efficacy of artemether using nanostructured lipid carriers.
Vanka R; Kuppusamy G; Praveen Kumar S; Baruah UK; Karri VVSR; Pandey V; Babu PP
J Microencapsul; 2018 Mar; 35(2):121-136. PubMed ID: 29448884
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of antimalarial potential of polyphosphazene linked combination therapy of primaquine and dihydroartemisinin.
Kumar S; Singh RK; Sharma R; Murthy RS; Bhardwaj TR
Eur J Pharm Sci; 2015 Jan; 66():123-37. PubMed ID: 25312346
[TBL] [Abstract][Full Text] [Related]
12. Plasmodium berghei K13 Mutations Mediate
Simwela NV; Stokes BH; Aghabi D; Bogyo M; Fidock DA; Waters AP
mBio; 2020 Nov; 11(6):. PubMed ID: 33173001
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of arteether-loaded nanostructured lipid carriers for the treatment of malaria.
Ali Z; Mishra N; Baldi A
Artif Cells Nanomed Biotechnol; 2016; 44(2):545-9. PubMed ID: 25340261
[TBL] [Abstract][Full Text] [Related]
14. Stearylamine Liposomal Delivery of Monensin in Combination with Free Artemisinin Eliminates Blood Stages of Plasmodium falciparum in Culture and P. berghei Infection in Murine Malaria.
Rajendran V; Rohra S; Raza M; Hasan GM; Dutt S; Ghosh PC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1304-18. PubMed ID: 26666937
[TBL] [Abstract][Full Text] [Related]
15. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial.
Tran TH; Dolecek C; Pham PM; Nguyen TD; Nguyen TT; Le HT; Dong TH; Tran TT; Stepniewska K; White NJ; Farrar J
Lancet; 2004 Jan; 363(9402):18-22. PubMed ID: 14723988
[TBL] [Abstract][Full Text] [Related]
16. Comparison of in vivo and in vitro antimalarial activity of artemisinin, dihydroartemisinin and sodium artesunate in the Plasmodium berghei-rodent model.
Janse CJ; Waters AP; Kos J; Lugt CB
Int J Parasitol; 1994 Jul; 24(4):589-94. PubMed ID: 8082988
[TBL] [Abstract][Full Text] [Related]
17. Curcumin-artemisinin combination therapy for malaria.
Nandakumar DN; Nagaraj VA; Vathsala PG; Rangarajan P; Padmanaban G
Antimicrob Agents Chemother; 2006 May; 50(5):1859-60. PubMed ID: 16641461
[TBL] [Abstract][Full Text] [Related]
18. NANOPARTICLE-BASED formulation of dihydroartemisinin-lumefantrine duo-drugs: Preclinical Evaluation and enhanced antimalarial efficacy in a mouse model.
Odera PA; Otieno G; Onyango JO; Owuor JJ; Oloo FA; Ongas M; Gathirwa J; Ogutu B
Heliyon; 2024 Mar; 10(6):e26868. PubMed ID: 38501019
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antiplasmodial activity of a synthetic dihydroartemisinin-eosin B hybrid.
Askarani HK; Tahghighi A; Ahmadpoor M; Zamani Z
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4013-4024. PubMed ID: 37999757
[TBL] [Abstract][Full Text] [Related]
20. Combination of zingerone and dihydroartemisinin presented synergistic antimalarial activity against Plasmodium berghei infection in BALB/c mice as in vivo model.
Ounjaijean S; Somsak V
Parasitol Int; 2020 Jun; 76():102088. PubMed ID: 32087333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
